Thermo Fisher Scientific Inc. $TMO Holdings Lifted by Fairtree Asset Management Pty Ltd

Fairtree Asset Management Pty Ltd increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,944 shares of the medical research company’s stock after acquiring an additional 2,409 shares during the period. Thermo Fisher Scientific comprises about 2.5% of Fairtree Asset Management Pty Ltd’s holdings, making the stock its 9th largest holding. Fairtree Asset Management Pty Ltd’s holdings in Thermo Fisher Scientific were worth $3,853,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $2,264,615,000. Soundwatch Capital LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $807,713,000. Flossbach Von Storch SE grew its holdings in shares of Thermo Fisher Scientific by 93.0% during the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after acquiring an additional 1,314,182 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Thermo Fisher Scientific by 54.7% in the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock worth $1,732,422,000 after acquiring an additional 1,262,967 shares during the last quarter. Finally, EdgePoint Investment Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 282.5% during the second quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock worth $536,450,000 after acquiring an additional 977,127 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on TMO. The Goldman Sachs Group began coverage on Thermo Fisher Scientific in a research note on Tuesday, December 9th. They set a “buy” rating and a $685.00 price target for the company. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Evercore reissued an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, UBS Group reiterated a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $633.68.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 22,046 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the sale, the chief operating officer directly owned 84,117 shares in the company, valued at $47,404,976.52. This trade represents a 20.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at $11,230,982.40. This represents a 1.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 91,358 shares of company stock valued at $52,789,173 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.1%

Shares of NYSE:TMO opened at $520.80 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The stock’s 50-day moving average is $574.24 and its 200-day moving average is $548.38. The company has a market cap of $193.47 billion, a P/E ratio of 29.36, a P/E/G ratio of 3.01 and a beta of 0.96. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.45 by $0.12. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.10 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 9.70%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.